Advocacy intelligence hub — real-time data for patient organizations
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
MEKINIST
(trametinib)Orphan drugstandardNovartis Pharmaceuticals Corp.
12.1 Mechanism of Action Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation ...
Browse all Fragile X-associated primary ovarian insufficiency news →
E Scott Sills, MD PhD
Center for Advanced Genetics (CAG)
Sophie Christin-Maitre, MD, PhD
Saint-Antoine hospital, Service of Endocrinology, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Karen Usdin
National Institute of Diabetes
Claudine M Kraan
The University of Melbourne
Laia Rodriguez-Revenga
Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Jonathan Cohen
Fragile X Alliance Clinic
View all Fragile X-associated primary ovarian insufficiency specialists →